{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-25-009199","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2025-07-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.974851+00:00","generated_at":"2026-05-18T06:13:26.696285+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Tonix plans 70-90 sales reps for TNX-102 SL if FDA approves fibromyalgia NDA","bullets":["Company plans to hire 70-90 sales representatives for TNX-102 SL conditional on FDA approval of NDA for fibromyalgia.","TNX-102 SL NDA is under FDA review; approval decision would trigger commercial launch planning.","Updated corporate presentation filed as Exhibit 99.01 for investor meetings; may contain nonpublic information."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-25-009199","json":"https://secwatch.observer/filing/0001999371-25-009199.json","markdown":"https://secwatch.observer/filing/0001999371-25-009199.md","text":"https://secwatch.observer/filing/0001999371-25-009199.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125009199/0001999371-25-009199-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125009199/tnxp-8k_071625.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:13:26.696285+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}